A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation

The purpose of this study is to evaluate the effect of BMS-919373 on atrial fibrillation (AF) through its effect on AF burden (AFB), or the percent of time in AF, in subjects with paroxysmal AF (pAF) when administered orally at a range of doses (2 mg once daily (QD), 5 mg QD, 12 mg QD following a 1-week period of loading doses of 3 mg QD, 8 mg QD and 20 mg QD, respectively) for a total of 4 weeks. It is hypothesized that treatment with BMS-919373 will reduce AF burden as compared to baseline relative to placebo.

Start Date25 Jul 2014

Sponsor / Collaborator

Bristol Myers Squibb Co.

NCT02089061 / CompletedPhase 1

A Phase 1 Open-label, Single-sequence Study to Evaluate the Effect of Coadministration of BMS-919373 on the Single-dose Pharmacokinetics of Rosuvastatin and Atorvastatin in Healthy Subjects

This purpose of this study is to assess the effects of BMS-919373 on the single dose Pharmacokinetics (PK) of Rosuvastatin and Atorvastatin in healthy subjects.

Start Date01 Mar 2014

Sponsor / Collaborator

Bristol Myers Squibb Co.

100 Clinical Results associated with BMS-919373

100 Translational Medicine associated with BMS-919373

100 Patents (Medical) associated with BMS-919373

Literatures (Medical) associated with BMS-919373

19 Apr 2019·The Journal of Organic ChemistryQ2 · CHEMISTRY

Utilizing Native Directing Groups: Synthesis of a Selective I_Kur Inhibitor, BMS-919373, via a Regioselective C–H Arylation

Q2 · CHEMISTRY

Article

Author: Fraunhoffer, Kenneth J. ; Savage, Scott A. ; Wisniewski, Steven R. ; Romero, Evan O. ; Stevens, Jason M. ; Yu, Miao

BMS-919373 is a highly functionalized quinazoline under investigation as a selective, potent I_Kur current blocker. By utilizing the aminomethylpyridine side chain at C-4, a selective C-H functionalization at C-5 was invented, enabling the efficient synthesis of this molecule. The strategy of leveraging this inherent directing group allowed the synthesis of this complex heterocycle in only six steps from commodity chemicals. The scope of the C-H activation was further investigated, and the generality of the transformation across a series of bicyclic aromatic heterocycles was explored.

100 Deals associated with BMS-919373

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15047

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Atrial Fibrillation	Phase 2	CA	Bristol Myers Squibb Co.	25 Jul 2014
Atrial Fibrillation	Phase 2	US	Bristol Myers Squibb Co.	25 Jul 2014
Acute Coronary Syndrome	Phase 2	-	Bristol Myers Squibb Co.	01 Mar 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02156076 (CTgov)	Phase 2	Atrial Fibrillation	158	BMS-919373 (BMS-919373 3/2 mg)	vtsrtommuq(ahhsdwurgn) = trndttihci ehjgsgbpvq (ycpopqsnkc, dlwiomniko - iavvtxzfrw) View more	-	22 May 2019
				BMS-919373 (BMS-919373 8/5 mg)	vtsrtommuq(ahhsdwurgn) = icjmnkjxrw ehjgsgbpvq (ycpopqsnkc, jneooskcka - gldharacoh) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis